With LABA Safety Under Fire, Novartis Addresses Post-Market Studies
Executive Summary
Novartis AG is evaluating how to move forward with FDA's extensive new post-marketing safety requirements for long-acting beta agonists as part of its ongoing review of the safety of their use in asthma.
You may also be interested in...
Novartis Cuts 2,000 Jobs In Switzerland And U.S., Pricing Pressures To Blame
Novartis intends to improve productivity and absorb pricing pressures by closing two Swiss manufacturing facilities and transferring some research to the U.S.
Novartis Cuts 2,000 Jobs In Switzerland And U.S., Pricing Pressures To Blame
Novartis intends to improve productivity and absorb pricing pressures by closing two Swiss manufacturing facilities and transferring some research to the U.S.
FDA Supersizes Its Order For LABA Safety Studies
The trials, which follow a label change and new REMS, will encompass seven times the patients included in the studies submitted to FDA for approval.